Apellis Pharmaceuticals, Inc. 4

Chief Scientific Officer Pascal Deschatelets effectively disposed of 1,177,222 shares of Apellis Pharmaceuticals common stock and had all related RSUs and stock options cancelled or cashed out at $41.00 per share plus CVRs in connection with Biogen’s merger with Apellis.

On May 14, 2026, in connection with the closing of Biogen Inc.’s acquisition of Apellis Pharmaceuticals, Inc., Chief Scientific Officer Pascal Deschatelets’ equity in Apellis was effectively cashed out and cancelled. A total of 1,177,222 shares of Apellis common stock previously held directly were exchanged in the tender offer/merger for $41.00 per share in cash plus one contingent value right (CVR) per share, and the Form 4 reflects this as a disposition transaction that reduced his direct common stock holdings to zero. Multiple restricted stock unit (RSU) awards covering 41,250; 10,030; 12,920; and 25,840 shares were converted into cash and CVRs, with parallel entries showing the RSU-based acquisition of common stock and its immediate disposition as part of the merger consideration, again resulting in no remaining direct stock from those awards. Additionally, a series of previously granted stock options with exercise prices ranging from $4.31 to $66.30 per share and share counts from 9,805 up to 110,000 were cancelled pursuant to the merger agreement; options with strike prices below $41.00 or between $41.00 and $45.00 were converted into the right to receive cash based on intrinsic value and/or CVRs, while those at or above $45.00 were cancelled without consideration. Following these merger-driven conversions and cancellations, Deschatelets reported no remaining direct ownership of Apellis common stock or options, consistent with Apellis becoming a wholly owned subsidiary of Biogen.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224609

Alert Tier

6